Biotechnology Innovation Organization’s Post

Navigate the ins and outs of strategic industry partnerships with Adam Hostetler, Director of Business Operations at Cook MyoSite, in this upcoming webinar! Register for free and uncover key strategies and best practices for developing a successful biotech partnership >>> https://hubs.ly/Q02xfyJR0

We are ramping up to the @HealthTech Investor Summit in three weeks from now. And what better way to do so than opening up our office to the start-up and scale-up companies and host a workshop from @Medvia on ‘What investors are looking for’. Yesterday, we welcomed more than 20 companies to directly learn from investors about how they work, what they’re after and how they analyze companies pitching their solutions. One of the key learnings: Finding the right investor, and type of investment is a marathon not a sprint: Along that journey, it is always worthwhile connecting with investors that could support a next growth step. We look forward to seeing all the valuable learnings applied in the pitches at the @HealthTech Investor Summit - Good luck to all companies pitching there! #HTIS24 #PwCBelgium #ProudPlatinumSponsor #Lifesciences #Pharma #Biotech

Today's headline from Fierce Biotech was an article from James Waldron titled "Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs." Nice to see the #IPO market opening for biotech and that public markets apetitite for biotech remains alive and well. https://lnkd.in/eDHwgq7x For the year, public investment in biotech is trending towards the third highest total on record. (Data on public investment to date from BioCentury Inc.) Center for Integration of Science and Industry at Bentley University

Should biotech companies consider pricing implications for Early Access Programs? In this snippet from our recent webinar with Fierce Biotech, Andrew Cummins (VP of Business Development) gives his expert thoughts and advice. Download valuable insights from our latest webinar! Visit: https://lnkd.in/eP4C3bFU #ExpandedAccessPrograms #RareDiseases #OrphanDrugs #RealWorldEvidence #MarketAccess #biotechs Mathieu Loiseau Sara Radenovic

Are you wondering how to establish an EAP in Europe without a local presence? Navigating the complexities of setting up and managing an Expanded Access Program (EAP) across 27 diverse European markets can be challenging. If you’re unsure where to start, don’t miss this snippet from our recent webinar with Fierce Biotech. Andrew Cummins, VP of Business Development, shares his expert strategies to successfully launch an EAP in Europe. Download valuable insights from our latest webinar! Visit: https://lnkd.in/eP4C3bFU #ExpandedAccessPrograms #RareDiseases #OrphanDrugs #RealWorldEvidence #MarketAccess #biotechs #Webinarrecap

As development cost and complexity continue to increase, it is more important than ever for biotech to be more intentional with the deployment of the funds they secure. In part two of our biotech funding whitepaper series, we share practical considerations to improve asset development programs across operational strategies, acceleration, regulatory, value-building and partnership aspects. https://ow.ly/uyH350RrYLy

🔬 📈 Biotech investors and corporate development professionals We've just launched Gosset, the platform that provides insights about biotech assets. Try our demo here: https://lnkd.in/gK2mUiTm and comment on this post to get early access to the full version (or just to help us spread the word:)

Amidst challenges, our sector remains resilient and is on the rise 🚀 Explore the insights in our UK biotech financing 2023 report as we celebrate the sector’s triumphs and its pivotal role in shaping a healthier future for millions 👩⚕️ ➡️ https://lnkd.in/e94GgQWd #InvestinBiotech

Two reason why TLDR Biotech is different. ("Why should I sign up to ANOTHER biotech/pharma newsletter?") 1) Just like you, I'm signed up to the usual suspects of biotech/pharma news reporting, and they all do fantastic work (and I link out to them within my newsletter). But the challenge I faced was receiving multiple, unorganized emails per day (and I'm sure your inbox is squeaky clean and you don't miss any emails...right?). TLDR Biotech only sends you one email per day, and all the stories are categorized - easy peasy! 2) Since TLDR Biotech is pulling from multiple news sources, there are some stories that you'll read here first. You might get the story straight from the horse's mouth (eg. corporate press releases), or from non-industry sources (eg. FinSME for fundraises). So if you're looking for a single source for your top biotech/pharma news, TLDR Biotech is it - you can subscribe here: https://bit.ly/3RdvHGu #tldrbiotech #biotechnews #pharmanews

Two reason why TLDR Biotech is different. ("Why should I sign up to ANOTHER biotech/pharma newsletter?") 1) Just like you, I'm signed up to the usual suspects of biotech/pharma news reporting, and they all do fantastic work (and I link out to them within my newsletter). But the challenge I faced was receiving multiple, unorganized emails per day (and I'm sure your inbox is squeaky clean and you don't miss any emails...right?). TLDR Biotech only sends you one email per day, and all the stories are categorized - easy peasy! 2) Since TLDR Biotech is pulling from multiple news sources, there are some stories that you'll read here first. You might get the story straight from the horse's mouth (eg. corporate press releases), or from non-industry sources (eg. FinSME for fundraises). So if you're looking for a single source for your top biotech/pharma news, TLDR Biotech is it - you can subscribe here: https://bit.ly/3RdvHGu #tldrbiotech #biotechnews #pharmanews